Holen Sie sich die Stockscreener-App
28.00
0.18%
0.05
Handel nachbörslich:
28.13
0.13
+0.46%
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com
Decoding MBX Biosciences Inc (MBX): A Strategic SWOT Insight - GuruFocus
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026 - Meyka
Truist reiterates Buy on MBX Biosciences stock, $50 target - Investing.com Nigeria
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target - Investing.com UK
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target By Investing.com - Investing.com UK
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III - Investing.com
Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Bitget
MBX: Advanced clinical pipeline and raised capital, supporting operations into 2029 - TradingView
MBX Biosciences 10-K: Operating loss $98.1M, Net loss $87.0M — cash runway into 2029 - TradingView
MBX: Phase 3 for hypoparathyroidism starts in Q3, with major obesity and PBH data readouts ahead - TradingView
Is MBX Biosciences’ (MBX) Regulatory Win and Leadership Refresh Reframing Its Hypoparathyroidism Strategy? - simplywall.st
Executives to engage with investors at key biotech events, MBX Biosciences outlines - Traders Union
MBX: FDA-aligned phase 3, strong pipeline, and funding secured for long-acting endocrine therapies - TradingView
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - BioSpace
MBX Biosciences (NASDAQ:MBX) Stock Price Down 7.3%What's Next? - MarketBeat
MBX Biosciences to Initiate Phase 3 Trial of Once-Weekly Canvuparatide for Hypoparathyroidism Following Successful FDA End-of-Phase 2 Meeting - Minichart
MBX Biosciences completes FDA meeting for Phase 3 trial design By Investing.com - Investing.com South Africa
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com India
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - The Manila Times
Truist reiterates MBX Biosciences stock rating after FDA meeting By Investing.com - Investing.com Canada
Weekly hypoparathyroidism drug set for 2026 Phase 3 after FDA talks - Stock Titan
Truist reiterates MBX Biosciences stock rating after FDA meeting - Investing.com Australia
MBX Biosciences Advances Canvuparatide After Phase 2 FDA Meeting - TipRanks
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - Bitget
MBX Biosciences, Inc. completes End-of-Phase 2 FDA meeting for chronic hypoparathyroidism therapy - Traders Union
MBX Biosciences to start Phase 3 trial for once-weekly canvuparatide in Q3 2026 after successful FDA EOP2 - TradingView
Weekly drug for hormone disorder heads to 160-patient trial - Stock Titan
MBX Biosciences CFO Shift Puts Funding And Execution In Focus - Yahoo Finance
Assessing MBX Biosciences (MBX) Valuation After Strong One Year Return And Recent Share Price Weakness - Sahm
MBX Biosciences CEO and CMO join key investor events at Citizens Bank conference and UBS Biotech Summit - Traders Union
TD Asset Management Inc Lowers Position in MBX Biosciences, Inc. $MBX - MarketBeat
Loss Report: Is MBX Biosciences Inc benefiting from interest rate changesTrend Reversal & Technical Buy Zone Confirmations - baoquankhu1.vn
MBX Biosciences annonce une offre d'actions après un doublement de l'action - TradingView
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MBX: Phase III and obesity data milestones, robust pipeline, and strong cash position drive outlook - TradingView
MBX: Clinically validated platform and robust pipeline drive multiple catalysts and strong financial outlook - TradingView
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Tech Rally: Is MBX Biosciences Inc benefiting from interest rate changesQuarterly Portfolio Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway - Yahoo Finance
MBX Biosciences, Inc. (MBX) Stock Report: Analyzing a 74% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
MBX Biosciences (MBX) CEO exercises stock options into 28,768 shares - Stock Titan
MBX Biosciences announces CFO transition and new lease for Massachusetts facility - Investing.com Australia
MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief - marketscreener.com
MBX Biosciences Announces CFO Transition and Interim Appointment - TipRanks
MBX appoints John Smither as Interim CFO as Richard Bartram to resign - TradingView
MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan
MBX Biosciences, Inc. Announces CFO Changes - marketscreener.com
MBX: Major clinical milestones and strong financials position for leadership in endocrine and obesity therapies - TradingView
UBS Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Feb 2026 - Meyka
UBS reiterates Buy on MBX Biosciences stock, keeps $60 target By Investing.com - Investing.com Australia
UBS reiterates Buy on MBX Biosciences stock, keeps $60 target - Investing.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):